36.1 Review of the Female Reproductive System

Female Reproductive System

The female reproductive system enables reproduction through a coordinated network of organs and hormones. In pharmacology, this system matters because many drugs target these hormones or structures directly, whether for contraception, fertility treatment, or managing menopause.

Ovaries, Fallopian Tubes, Uterus, Cervix, Vagina

Each organ in the reproductive tract has a distinct role, and many reproductive drugs act on specific structures or the hormones they produce.

• Ovaries produce and release eggs (ova) and secrete the two major female sex hormones: estrogen and progesterone. These hormones drive the menstrual cycle and are the primary targets of hormonal contraceptives and hormone replacement therapy.
• Fallopian tubes transport the egg from the ovary toward the uterus. Fertilization typically occurs here, within the tube itself.
• Uterus provides the environment for fetal development. Its inner lining, the endometrium, thickens each cycle in preparation for implantation. If pregnancy doesn't occur, the endometrium sheds during menstruation.
• Cervix produces mucus that changes consistency throughout the cycle. Around ovulation, cervical mucus thins to help sperm entry; at other times, it thickens to block sperm. Progestin-only contraceptives work partly by keeping this mucus thick.
• Vagina serves as the birth canal during delivery and is the site affected by atrophic changes during menopause.

Hormonal Regulation of the Menstrual Cycle

The menstrual cycle is controlled by a feedback loop between the hypothalamus, anterior pituitary gland, and ovaries. This is often called the hypothalamic-pituitary-ovarian (HPO) axis. Disrupting this axis is exactly how most hormonal contraceptives prevent pregnancy.

Here's how a typical 28-day cycle progresses:

1. GnRH release: The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses, which signals the anterior pituitary to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

2. Follicular phase (days 1–13): FSH stimulates several ovarian follicles to grow, each containing an immature egg. As follicles develop, they secrete rising levels of estrogen, which thickens the endometrium. Eventually one dominant follicle outgrows the rest.

3. Ovulation (around day 14): A sharp LH surge triggers the dominant follicle to rupture and release a mature egg. This is the most fertile point of the cycle.

4. Luteal phase (days 15–28): The ruptured follicle transforms into the corpus luteum, which secretes progesterone and some estrogen. Progesterone stabilizes the endometrium and makes it receptive to implantation. It also raises basal body temperature slightly.

5. Menstruation (days 1–7 of the next cycle): If implantation doesn't occur, the corpus luteum degenerates. The resulting drop in progesterone and estrogen causes the endometrium to shed, producing menstrual flow lasting about 3–7 days. This marks day 1 of a new cycle.

Menopause: Changes and Health Considerations

Menopause is the permanent cessation of menstruation and fertility. It's diagnosed after 12 consecutive months of amenorrhea and typically occurs between ages 45 and 55. The transition leading up to it, called perimenopause, can last several years and involves increasingly irregular cycles.

The root cause is a gradual decline in ovarian estrogen and progesterone production. As hormone levels fluctuate and eventually drop, several symptoms and health risks emerge:

• Vasomotor symptoms: hot flashes and night sweats (the most commonly reported complaints)
• Genitourinary syndrome of menopause (GSM): vaginal dryness, irritation, painful intercourse, and urinary symptoms like urgency or recurrent UTIs
• Mood and sleep changes: increased anxiety, irritability, and sleep disturbances
• Bone loss: decreased estrogen accelerates osteoclast activity, raising the risk of osteoporosis significantly
• Cardiovascular risk: the protective effect of estrogen on blood vessels diminishes, and cardiovascular disease risk rises after menopause

Management options are a frequent pharmacology topic:

• Hormone replacement therapy (HRT): systemic estrogen (with progestin if the patient has a uterus, to prevent endometrial hyperplasia) alleviates vasomotor symptoms and protects bone density. Low-dose vaginal estrogen treats GSM locally with minimal systemic absorption.
• Non-hormonal pharmacologic options: SSRIs/SNRIs (e.g., paroxetine, venlafaxine) for hot flashes, ospemifene for vaginal atrophy, and bisphosphonates for osteoporosis prevention.
• Lifestyle modifications: weight-bearing exercise for bone health, balanced diet with adequate calcium and vitamin D, and stress reduction techniques.